Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation.
Adult
Allografts
Benzylamines
Busulfan
/ administration & dosage
Cyclams
Female
Granulocyte Colony-Stimulating Factor
/ administration & dosage
Hematopoietic Stem Cell Mobilization
Heterocyclic Compounds
/ administration & dosage
Humans
Leukemia, Myeloid, Acute
/ metabolism
Male
Middle Aged
Neoplasm Proteins
/ metabolism
Proteomics
Signal Transduction
Transplantation Conditioning
Vidarabine
/ administration & dosage
Acute myeloid leukemia
Allogeneic stem cell transplantation
CXCR4
Plerixafor
Proteomic profiling of signaling
Journal
Acta haematologica
ISSN: 1421-9662
Titre abrégé: Acta Haematol
Pays: Switzerland
ID NLM: 0141053
Informations de publication
Date de publication:
2019
2019
Historique:
received:
15
11
2018
accepted:
15
11
2018
pubmed:
22
5
2019
medline:
12
2
2020
entrez:
22
5
2019
Statut:
ppublish
Résumé
To characterize intracellular signaling in peripheral blood (PB) cells of acute myeloid leukemia (AML) patients undergoing pretransplant conditioning with CXCR4 inhibitor plerixafor, granulocyte colony-stimulating factor (G-CSF), and busulfan plus fludarabine (Bu+Flu) chemotherapy, we profiled 153 proteins in 33 functional groups using reverse phase protein array. CXCR4 inhibition mobilized AML progenitors and clonal AML cells, and this was associated with molecular markers of cell cycle progression. G-CSF/plerixafor and G-CSF/plerixafor/Bu+Flu modulated distinct signaling networks in AML blasts of patients undergoing conditioning with active disease compared to nonleukemic PB cells of patients in remission. We identified AML-specific proteins that remained aberrantly expressed after chemotherapy, representing putative chemoresistance markers in AML.
Identifiants
pubmed: 31112940
pii: 000495456
doi: 10.1159/000495456
pmc: PMC6792289
mid: NIHMS1054463
doi:
Substances chimiques
Benzylamines
0
Cyclams
0
Heterocyclic Compounds
0
Neoplasm Proteins
0
Granulocyte Colony-Stimulating Factor
143011-72-7
Vidarabine
FA2DM6879K
Busulfan
G1LN9045DK
fludarabine
P2K93U8740
plerixafor
S915P5499N
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
176-184Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA137637
Pays : United States
Informations de copyright
© 2018 S. Karger AG, Basel.
Références
Blood. 2009 Jan 1;113(1):154-64
pubmed: 18840713
Cells. 2017 May 04;6(2):null
pubmed: 28471392
Biol Blood Marrow Transplant. 2005 Feb;11(2):108-14
pubmed: 15682071
J Exp Med. 2010 Nov 22;207(12):2631-45
pubmed: 20975039
Biochim Biophys Acta. 2007 Apr;1768(4):952-63
pubmed: 17169327
Br J Haematol. 2008 Sep;142(5):831-5
pubmed: 18540940
Biol Blood Marrow Transplant. 2003 Dec;9(12):766-71
pubmed: 14677116
Blood Cancer J. 2017 Mar 10;7(3):e542
pubmed: 28282031
Cancer Cell. 2016 Jan 11;29(1):61-74
pubmed: 26766591
Blood. 2009 Jun 4;113(23):5720-6
pubmed: 19363221
Bone Marrow Transplant. 2015 Jul;50(7):939-946
pubmed: 25867648
Blood. 2017 May 25;129(21):2939-2949
pubmed: 28400375
Bone Marrow Transplant. 2000 Dec;26(11):1157-63
pubmed: 11149725
Cell. 2007 Jun 15;129(6):1081-95
pubmed: 17574022
J Clin Oncol. 2010 Aug 10;28(23):3730-8
pubmed: 20625136
J Clin Oncol. 2009 Oct 1;27(28):4767-73
pubmed: 19720922
Blood. 2012 Apr 26;119(17):3917-24
pubmed: 22308295
Blood. 2009 Jun 11;113(24):6215-24
pubmed: 18955566
Blood. 2009 Jun 11;113(24):6206-14
pubmed: 19050309
Leukemia. 1997 Nov;11(11):1850-7
pubmed: 9369417
Bioinformatics. 2007 Aug 1;23(15):1986-94
pubmed: 17599930
Cancer Inform. 2012;11:77-86
pubmed: 22550399
Mol Cancer Ther. 2006 Oct;5(10):2512-21
pubmed: 17041095